** Shares of drug developer Atara Biotherapeutics ATRA.O fall 4.6% to $6.27 premarket
** Co says the US FDA has placed a clinical hold on trials testing its experimental cancer cell therapies
** The hold applies to studies of co's experimental cancer therapies, tabelecleucel, and ATA3219
** Co says the hold is related to the issues observed at a third-party manufacturing facility
** The FDA last week declined to approve its cancer therapy tabelecleucel to treat patients with a rare cancer that develops after organ or stem cell transplants, due to third-party manufacturing concerns
** "Atara and FDA have discussed and agreed upon the actions necessary to release the clinical holds"- ATRA
** Co says it has paused enrollment of new participants in the trials; adding that some participants "who have the potential to derive clinical benefit" can continue to receive treatment
** Up last close, stock had fallen 63.2% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。